

IOptima - Obtained regulatory approval for the sales and marketing of the IOptiMate™ system in Taiwan

TEL-AVIV (August 28, 2017) – BioLight Life Sciences Ltd. (TASE: BOLT) , an emerging global ophthalmic company focused on the discovery, development and commercialization of ophthalmic products and product candidates, announced today that on August 27, 2017, IOptima Ltd., a subsidiary of the Company ("IOptima"), announced that it has received regulatory approval from the Taiwan Ministry of Health (TFDA) for the sales and marketing of the IOptiMate™ system of IOptima, a CO2 laser assisted surgical system enabling glaucoma surgery without penetrating the eye .

IOptima has a distribution agreement with a distributor in Taiwan with which intends to sell and market IOptiMate™ system in that country.

The regulatory approval in Taiwan joins the additional approvals received by IOptima for sales and marketing of the IOptiMate™ system in various territories, including Europe (CE Mark), Mexico (COFEPRIS), China (CFDA), Israel (AMD), Peru (DIGEMID), Thailand (Thai FDA) and Canada (CMBD) and strengthens the competitive position of IOptima in these territories.

